Showing results (2591-2600 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 22, 2022
A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjectsFangfang Ding, Jie Huang, Zeying Feng, et al.
Investigational New Drugs|January 1, 1986
Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studiesF Ganzina, M A Pacciarini, N Di Pietro
Investigational New Drugs|October 6, 2021
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumorsElisabeth I Heath, Amy Weise, Ulka Vaishampayan, et al.
Investigational New Drugs|January 1, 1987
Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cellsJ P Kuebler, T D Oberley, L F Meisner, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
Investigational New Drugs|May 19, 2019
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cellsDorival Mendes Rodrigues-Junior, Nicolie Melanie de Almeida Pontes, Gabriela Estrela de Albuquerque, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Investigational New Drugs|June 3, 2019
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cellsPaola Orlandi, Daniela Gentile, Marta Banchi, et al.
Investigational New Drugs|October 15, 2018
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimensJ R Goffin, G Nicholas, M Mates, et al.
Investigational New Drugs|September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory studyRony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Pageof 372